Tendinopathy

In an innovative step towards combating chronic pain, Bestqool, a leader in therapeutic devices, unveils a new range of red light therapy products designed to provide relief from back, waist, neck, and shoulder pain. This breakthrough approach harnesses the power of red and near-infrared light wavelengths, offering a drug-free alternative to traditional pain management techniques. Back pain affects about 80% of adults at some point in their lives. This widespread problem may have a big influence on our everyday lives and health. Bestqool's latest offering is inspired by centuries of phototherapy research, from the ancient Egyptians' use of sunlight to the latest scientific findings on the benefits of red light therapy (RLT). Light’s therapeutic potential has been studied for centuries, starting with the ancient Egyptians, who used sunlight to treat a variety of ailments and continuing into modern scientific research. In phototherapy, red light therapy is an emerging miraculous therapy. It works by penetrating the skin and accelerating cellular processes with particular red and near-infrared light wavelengths. According to studies, this therapy can help relieve pain in the back, waist, neck, and shoulders by reducing inflammation, promoting tissue healing and not requiring the use of drugs. How Red Light Therapy Works Red light therapy operates by delivering specific wavelengths of light (660 - 850 nm) deep into the skin, stimulating cellular processes that facilitate pain relief. The therapy enhances mitochondrial function, thereby increasing the production of adenosine triphosphate (ATP), which is crucial for healing and reducing inflammation. Furthermore, it accelerates tissue repair and regeneration, making it an effective treatment for musculoskeletal pain. Increased Cellular Energy Production (ATP) Increasing the production of cellular energy (ATP) is one of red light therapy’s primary mechanisms of action. The “powerhouse” of the cell, the mitochondria, are activated to bring about this effect. These mitochondria boost the synthesis of ATP, the main energy source for different biological processes. Higher levels of ATP promote better cellular function, which lessens pain and promotes tissue healing. Reduction of Inflammation Red light therapy also works by reducing inflammation which is a major contributor to pain. Studies suggest that it can promote the activity of immune cells and other factors involved in the inflammatory response. By reducing this inflammatory response, red light therapy contributes to pain relief and accelerates tissue healing. Stimulation of tissue repair and regeneration Various studies indicate that red light therapy also stimulates tissue repair and regeneration. It promotes collagen production, an important protein for building and supporting tissues. Also, it enhances the activity of growth factors involved in tissue repair. This stimulation of repair mechanisms leads to faster healing and pain reduction in affected areas. Scientific Research Supporting RLT for Pain Relief More than 4000 scientific studies on pubmed.gov concluded that red light therapy has a positive effect on acute and chronic musculoskeletal pain. A notable review in the MOJ Orthopedics & Rheumatology journal highlighted its benefits for musculoskeletal discomfort, emphasizing its safety, cost-effectiveness, and role in enhancing the quality of life without the need for medication. st-effective therapy for pain could elevate quality of life while reducing financial strains. Red Light Therapy for Back and Waist Pain A study published in the European Journal of Scientific Research suggested that if infrared therapy is applied on the affected area (back or waist) with appropriate dose, exposure time and wavelength, it helps in relieving pain without any side effects. In 2020, another study on light-emitting diode photobiomodulation therapy for non-specific low back pain in working nurses was published in the journal “Medicine”. Patients received 6 LED red light therapy sessions (with wavelengths of both 630 nm and 850 nm) in two weeks. This study examined that LED therapy could be an effective alternative treatment for reducing non-specific back pain. Red Light Therapy for Shoulder Pain In a study published in 2022, ten adults with shoulder pain received LED red light therapy (wavelength 780 nm) for 3 minutes on the affected shoulder. After therapy, the symptoms of the neck with shoulder pain were improved. These symptoms improved further after 15 minutes of irradiation. It found that RLT is safe and effective for the treatment of shoulder pain. A systematic review and meta-analysis on the efficacy of low-level laser therapy for shoulder tendinopathy published in the journal Physiotherapy Research International in 2014 shows that optimal RLT can offer pain relief and induce a more rapid improvement, whether it is used alone or in combination with physiotherapy treatments. Red Light Therapy for Neck Pain A 2016 study published in the Journal “Functional Neurology, Rehabilitation, and Ergonomics found that red laser therapy is safe and effective for temporary pain relief and improving the range of motion for patients with chronic pain in the neck and shoulder caused by osteoarthritis, muscle spasms and cervical and thoracic spine strain. It also suggested that when RLT is used in conjunction with physical therapy and chiropractic care, it may help patients live normal, active and healthy lives without the need for analgesics. A systematic review in the Journal of Lasers in Surgery and Medicine analyzed various randomized controlled trials and suggested that infrared laser therapy helps in the treatment of acute and chronic neck pain. Another research in the Open Orthopedics Journal showed that red light therapy can moderately reduce chronic neck pain. Red Light Therapy Parameters For red light therapy to be effective, the irradiation parameters (wavelength, power, power density, pulse parameters, energy density, total energy and time) must fall within specific ranges. The optimum penetrating wavelengths fall between 660–850nm, and at 5 cm depth, they can reach a light density of 5 mW/cm2 when the surface density is 5 mW/cm2, and the beam power is 1 watt. RLT has four clinical objectives: To promote healing, remodeling and reduce inflammation in the injured/affected area Lymph nodes to lessen inflammation and edema Nerves to induce numbness Trigger points to ease tenderness and relaxation of contracted muscles Treatment times per point range between 30 to 60 seconds on average. For simple cases, one point may be treated; however, for complex dysfunctions like lumbar radiculopathy or chronic pain, ten to fifteen points may be treated. Choosing the Best Red Light therapy If you are suffering from any chronic fatigue and pain, red light therapy devices like the ones offered by Bestqool can be a game-changer. It offers you a range of high-quality red light devices and portable devices to manage your pain with the benefit of lowering your reliance on pharmaceutical drugs. Whether you aim to get rid of chronic pain or to improve overall health, you can adjust treatment goals as per your needs. All Bestqool red light therapy devices are FDA class II cleared, and usage cannot directly cause any harm to the human body. Remember, red light therapy devices are not a substitute for professional medical treatment to cure diseases. Still, they can help people who are medically powerless and relieve their physical and mental discomfort. References Roche, G. C., Murphy, D. J., Berry, T. S., & Shanks, S. (2016). Low-level laser therapy for the treatment of chronic neck and shoulder pain. Functional Neurology, Rehabilitation, and Ergonomics, 6(2), 97. Cotler, H. B., Chow, R. T., Hamblin, M. R., & Carroll, J. (2015). The Use of Low Level Laser Therapy (LLLT) For Musculoskeletal Pain. MOJ orthopedics & rheumatology, 2(5), 00068. Haslerud, S., Magnussen, L. H., Joensen, J., Lopes‐Martins, R. A. B., & Bjordal, J. M. (2015). The efficacy of Low‐Level laser therapy for shoulder tendinopathy: a systematic review and Meta‐Analysis of randomized controlled trials. Physiotherapy Research International, 20(2), 108-125. Lin, Y. P., Su, Y. H., Chin, S. F., Chou, Y. C., & Chia, W. T. (2020). Light-emitting diode photobiomodulation therapy for non-specific low back pain in working nurses: A single-center, double-blind, prospective, randomized controlled trial. Medicine, 99(32), e21611. Chow, R. T., & Barnsley, L. (2005). Systematic review of the literature of low‐level laser therapy (LLLT) in the management of neck pain. Lasers in Surgery and Medicine: The Official Journal of the American Society for Laser Medicine and Surgery, 37(1), 46-52.

Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust clinical responses achieved for the high hurdles of ACR70, PASI100, as well as composite endpoints ACR50/PASI100 and Minimal Disease Activity Favorable safety profile consistent with the IL-17A class and previous izokibep experience March 11, 2024 -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced its global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis (PsA) met the primary endpoint of ACR50 at week 16 with high statistical significance. Results from the 160 mg weekly (QW) and every other week (Q2W) arms showed improved magnitude of responses on higher hurdle endpoints such as ACR70, PASI100, and Minimal Disease Activity relative to the Phase 2 80 mg Q2W dose. This is notable given a higher baseline disease burden in the Phase 2b/3 trial population relative to the Phase 2 trial. Izokibep was well-tolerated with a favorable safety profile consistent with previous experience and the IL-17A class, without evidence of the safety liabilities observed with targeting IL-17A&F. The trial had a low study discontinuation rate of Pre-specified analyses continue to support the potential for differentiation in enthesitis resolution. Consistent high magnitude absolute responses were demonstrated in the Phase 2-comparable population (baseline Leeds Enthesitis Index (LEI) 1 or 2) although enthesitis resolution overall was not statistically significant due to high placebo response. Izokibep achieved clinically meaningful resolution in patients with the highest burden of enthesitis (baseline LEI 3-6) relative to placebo an effect not previously reported by other agents. Additional information about these results can be found at ACELYRIN.com. Further data from this trial will be presented at future scientific meetings. “These positive Phase 2b/3 data reinforce the potential demonstrated in Phase 2 for izokibep to provide meaningful benefit in treating the debilitating signs and symptoms of active psoriatic arthritis in the joints and skin, as well as enthesitis where the results in the most severe patients are encouraging and warrant further study,” said Philip Mease, MD, MACR, Director of Rheumatology Research at Swedish Medical Center. “We have observed from the Phase 2 46-week data that there is no safety limitation to long-term treatment with izokibep and that longer duration of therapy demonstrated the potential for even further improvements over time.” “We are excited about our continued progress with izokibep in both PsA and HS,” said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN. “The positive PsA study results at week 16 and the magnitude of responses give us conviction that 160 mg Q2W delivers higher clinical responses than those reported by the approved IL-17A agents, and responses comparable to those reported by the IL-17A&F agents without the associated safety liabilities. Across indications, we have observed clinically meaningful and potentially differentiated benefit from izokibep. We have consistently seen responses in high order efficacy measures such as ACR70 and PASI100 in PsA and HiSCR100 in HS that move patients toward disease resolution. This reinforces our enthusiasm for developing izokibep as an important potential new medicine for patients.” The Phase 2b/3 clinical trial (NCT05623345) is a global, multi center, randomized double-blind, placebo-controlled, trial evaluating the safety and efficacy of izokibep dosed subcutaneously 160 mg every week (QW) or every two weeks (Q2W) and 80 mg every four weeks (Q4W) versus placebo. 351 adult patients with active PsA were enrolled across 71 sites in the United States and Europe and randomized across the four arms. Dose sequencing in the 160 mg Q2W and 80 mg Q4W arms was impacted by a third-party programming error. The range of pharmacokinetic data from both the 160 mg QW and Q2W arms in PsA demonstrated comparable exposures to the same dose levels from the Phase 2b HS study. Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease characterized by multiple manifestations including joint inflammation, skin lesions consistent with psoriasis, and enthesitis (painful inflammation of the small, dense tissues that connect ligament and tendons to bone), all contributing to reduced quality of life. It is estimated that approximately 30% of the 125 million people living with psoriasis worldwide will also develop PsA over time. There remains a large unmet need for more effective therapies to treat PsA across all disease manifestations. Izokibep is a small protein therapeutic designed to inhibit IL-17A with high potency through tight binding affinity, the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody, and an albumin binding domain that extends half-life. Clinical trial data supports the hypothesis that these unique characteristics of izokibep may provide clinically meaningful and differentiated benefits for patients, including resolution of key manifestations of disease. Izokibep is being evaluated in multiple late-stage trials in moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA). ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The content above comes from the network. if any infringement, please contact us to modify.

MISSION, Kan., March 11, 2024 /PRNewswire/ -- (Family Features) Millions of people experience chronic pain, with knee pain among the most common. Athletes and active adults know the impact activities like running and skiing can have on their knees, but when chronic knee pain makes it difficult to do those activities, or even day-to-day tasks like walking up the stairs, people may often face challenges. Continue Reading Photos courtesy of Shutterstock Photos courtesy of Shutterstock According to the journal "Cartilage," unlike other tissues, cartilage does not repair itself and, without proper treatment, can worsen over time and become more difficult to treat. However, options like FDA-approved knee cartilage repair surgery MACI (autologous cultured chondrocytes on porcine collagen membrane) uses a patient's cells to help repair cartilage defects and may help alleviate knee pain. "Sports-related pain should be evaluated quickly, especially when it's difficult to put weight on the knee, swelling occurs or there is restricted range of motion," said Dr. Alexander Meininger, orthopedic surgeon and MACI consultant. Justin Keys, a former patient of Meininger and avid skier, knows that the long-term outcomes of knee cartilage surgery can be worth the short-term sacrifices. After several injuries, including an ACL injury, Keys struggled with most activities except walking on flat, paved surfaces. After consulting with Meininger, Keys chose knee cartilage repair to help get back to his active lifestyle. Keys considered whether to manage the injury as-is or choose MACI and undergo rehabilitation to potentially get back to his favorite activities in the future. He knew he could no longer use short-term relief methods and had to address his pain with a treatment to help provide lasting relief. For athletes like Keys who want to fix knee pain, it's important to consider these steps: Discuss Options with Your Doctor Patients should talk to their doctors and undergo an MRI to help assess the internal structures of the knee. Meininger recommends patients and their doctors discuss options for long-term knee restoration health, preserving function for future decades and recognizing the short-term sacrifice. Set Yourself Up for Success Experts like Meininger suggest patients take steps ahead of surgery to help their recovery. "The important thing is to be as fit as possible and use the preseason months to undergo surgery and rehab," Meininger said. Patients can take steps to prep their home for recovery, which may include: Bringing necessities down from hard-to-reach shelves Moving furniture to ensure clear pathways Installing shower safety handles to minimize potential falls The Road to Rehab and Recovery Rehabilitation takes time and everyone's experience is unique. It can be as much of a mental challenge as it is physical. Committing to a physical therapy regime, staying hydrated and eating well are important aspects to support recovery. Patients should talk to their doctors with questions and before starting any exercises. IMPORTANT SAFETY INFORMATION Do not use if you are allergic to antibiotics such as gentamicin or materials from cow or pig; have severe osteoarthritis of the knee, other severe inflammatory conditions, infections or inflammation in the bone joint and other surrounding tissue or blood clotting conditions; had knee surgery in the past 6 months, not including surgery for obtaining a cartilage biopsy or a surgical procedure to prepare your knee for a MACI implant; or cannot follow a rehabilitation program post-surgery. MACI is used for the repair of symptomatic cartilage damage of the adult knee. Conditions that existed before your surgery, including meniscus tears, joint or ligament instability or alignment problems should be evaluated and treated before or at the same time as the MACI implant. MACI is not recommended if you are pregnant. MACI has not been studied in patients younger than 18 or over 55 years of age. Common side effects include joint pain, tendonitis, back pain, joint swelling and joint effusion. More serious side effects include joint pain, cartilage or meniscus injury, treatment failure and osteoarthritis. See Full Prescribing Information for more information. Find more information by visiting MACI.com. *Testimonials by MACI patient and paid Vericel consultant Photos courtesy of Shutterstock Michael French [email protected] 1-888-824-3337 editors.familyfeatures.com About Family Features Editorial Syndicate A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com. SOURCE Family Features Editorial Syndicate